Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer
Authors:
- Fumimasa KitamuraFKFumimasa Kitamura
- Takashi SembaTSTakashi Semba
- Noriko Yasuda-YoshiharaNYNoriko Yasuda-Yoshihara
- Kosuke YamadaKYKosuke Yamada
- Akiho NishimuraANAkiho Nishimura
- Juntaro YamasakiJYJuntaro Yamasaki
- Osamu NaganoONOsamu Nagano
- Tadahito YasudaTYTadahito Yasuda
- Atsuko YonemuraAYAtsuko Yonemura
- Yilin TongYTYilin Tong
- Huaitao WangHWHuaitao Wang
- Takahiko AkiyamaTATakahiko Akiyama
Top Cited Papers
Open Access
- 23 October 2023
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (20)
Abstract
Glycolysis is highly enhanced in pancreatic ductal adenocarcinoma (PDAC) cells; thus, glucose restrictions are imposed on nontumor cells in the PDAC tumor microenvironment (TME). However, little is known about how such glucose competition alters metabolism and confers phenotypic changes in stromal cells in the TME. Here, we report that cancer-associated fibroblasts (CAFs) with restricted glucose availability utilize lactate from glycolysis-enhanced cancer cells as a fuel and exert immunosuppressive activity in the PDAC TME. The expression of lactate dehydrogenase A (LDHA), which regulates lactate production, was a poor prognostic factor for patients with PDAC, and LDHA depletion suppressed tumor growth in a CAF-rich murine PDAC model. Coculture of CAFs with PDAC cells revealed that most of the glucose was taken up by the tumor cells and that CAFs consumed lactate via monocarboxylate transporter 1 to enhance proliferation through the TCA cycle. Moreover, lactate-stimulated CAFs upregulated IL-6 expression and suppressed cytotoxic immune cell activity synergistically with lactate. Finally, the LDHA inhibitor FX11 reduced tumor growth and improved antitumor immunity in CAF-rich PDAC tumors. Our study provides insight regarding the crosstalk among tumor cells, CAFs, and immune cells mediated by lactate and offers therapeutic strategies for targeting LDHA enzymatic activity in PDAC cells.Keywords
Funding Information
- the FOREST program of the Japan Science and Technology Agency (JPMJFR200H)
- Japan Society for the Promotion of Science (20H03531)
- Japan Society for the Promotion of Science (21K19535)
- Japan Society for the Promotion of Science (21KK0153)
- Japan Society for the Promotion of Science (20K09038)
- Japan Society for the Promotion of Science (20K08985)
- Japan Society for the Promotion of Science (21K6515)
- Japan Society for the Promotion of Science (22K08756)
This publication has 58 references indexed in Scilit:
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose MetabolismCell, 2012
- Targeting the Lactate Transporter MCT1 in Endothelial Cells Inhibits Lactate-Induced HIF-1 Activation and Tumor AngiogenesisPLOS ONE, 2012
- Lactate: A Metabolic Key Player in CancerCancer Research, 2011
- LDH-A silencing suppresses breast cancer tumorigenicity through induction of oxidative stress mediated mitochondrial pathway apoptosisBreast Cancer Research and Treatment, 2011
- Lactate Influx through the Endothelial Cell Monocarboxylate Transporter MCT1 Supports an NF-κB/IL-8 Pathway that Drives Tumor AngiogenesisCancer Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progressionProceedings of the National Academy of Sciences, 2010
- Inhibitory effect of tumor cell–derived lactic acid on human T cellsBlood, 2007
- Comparison of Metabolic Pathways between Cancer Cells and Stromal Cells in Colorectal Carcinomas: a Metabolic Survival Role for Tumor-Associated StromaCancer Research, 2006
- Growth factors, mitogens, oncogenes and the regulation of glucose transportCellular Signalling, 1993